StockData
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. (LXEO) stock

LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$2.85−0.38 (-11.61%)

Close on Nov 17, 2026Market cap $234.24MP/E –Yield –

Lexeo Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Lexeo Therapeutics's enterprise value was $7.17M on Nov 11, 2026, against $418.89M a year earlier. Over the last 3 years it ranged from -$33.92M to $422.73M, with a median of $120.45M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$7.17M-98.3%
2025Dec 31, 2025$422.73M+638.4%
2024Dec 31, 2024$57.25M–
2023Dec 29, 2023-$16.78M–

More Lexeo Therapeutics figures

See a number that looks wrong?